請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40503
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(Mark Yen-Ping Kuo) | |
dc.contributor.author | Chiao-Ying Lin | en |
dc.contributor.author | 林佼穎 | zh_TW |
dc.date.accessioned | 2021-06-14T16:49:32Z | - |
dc.date.available | 2008-09-11 | |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-29 | |
dc.identifier.citation | 1. Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev 2002;82:331-371.
2. Moss SE, Morgan RO: The annexins. Genome Biol 2004;5:219. 3. Creutz CE, Pazoles CJ, Pollard HB: Identification and purification of an adrenal medullary protein (synexin) that causes calcium-dependent aggregation of isolated chromaffin granules. J Biol Chem 1978;253:2858-2866. 4. Blackwell GJ, Carnuccio R, Di Rosa M, et al.: Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980;287:147-149. 5. Rothhut B, Russo-Marie F, Wood J, et al.: Further characterization of the glucocorticoid-induced antiphospholipase protein 'renocortin'. Biochem Biophys Res Commun 1983;117:878-884. 6. Hirata F, del Carmine R, Nelson CA, et al.: Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases. Proc Natl Acad Sci U S A 1981;78:3190-3194. 7. White JA, McAlpine PJ, Antonarakis S, et al.: Guidelines for human gene nomenclature (1997). HUGO Nomenclature Committee. Genomics 1997;45:468-471. 8. Fernandez MP MR: Structure, function and evolution of the annexin gene superfamily. . In Bandorowicz-, Pikula J. Georgetown TLB (eds): 'In The Annexins - Biological Importance and Annexin-related Pathologies. A summary of annexin gene structures, chromosomal maps and protein evolution. .' Landes Bioscience, 2003. 9. Raynal P, Pollard HB: Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994;1197:63-93. 10. Perretti M, Getting SJ, Solito E, et al.: Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol 2001;158:1969-1973. 11. Mailliard WS, Haigler HT, Schlaepfer DD: Calcium-dependent binding of S100C to the N-terminal domain of annexin I. J Biol Chem 1996;271:719-725. 12. Rosengarth A, Gerke V, Luecke H: X-ray structure of full-length annexin 1 and implications for membrane aggregation. J Mol Biol 2001;306:489-498. 13. Johnstone SA, Hubaishy I, Waisman DM: Regulation of annexin I-dependent aggregation of phospholipid vesicles by protein kinase C. Biochem J 1993;294 ( Pt 3):801-807. 14. Alldridge LC, Bryant CE: Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res 2003;290:93-107. 15. Tomas A, Moss SE: Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope. J Biol Chem 2003;278:20210-20216. 16. Eberhard DA, Karns LR, VandenBerg SR, Creutz CE: Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding. J Cell Sci 2001;114:3155-3166. 17. Solito E, Nuti S, Parente L: Dexamethasone-induced translocation of lipocortin (annexin) 1 to the cell membrane of U-937 cells. Br J Pharmacol 1994;112:347-348. 18. Brownstein C, Falcone DJ, Jacovina A, Hajjar KA: A mediator of cell surface-specific plasmin generation. Ann N Y Acad Sci 2001;947:143-155; discussion 155-146. 19. Liu SH, Lin CY, Peng SY, et al.: Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 2002;160:1831-1837. 20. Hannon R, Croxtall JD, Getting SJ, et al.: Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J 2003;17:253-255. 21. Futter CE, White IJ: Annexins and endocytosis. Traffic 2007;8:951-958. 22. Ling Q, Jacovina AT, Deora A, et al.: Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004;113:38-48. 23. Brachvogel B, Dikschas J, Moch H, et al.: Annexin A5 is not essential for skeletal development. Mol Cell Biol 2003;23:2907-2913. 24. Hawkins TE, Roes J, Rees D, et al.: Immunological development and cardiovascular function are normal in annexin VI null mutant mice. Mol Cell Biol 1999;19:8028-8032. 25. Herr C, Smyth N, Ullrich S, et al.: Loss of annexin A7 leads to alterations in frequency-induced shortening of isolated murine cardiomyocytes. Mol Cell Biol 2001;21:4119-4128. 26. Davidson FF, Dennis EA: Biological relevance of lipocortins and related proteins as inhibitors of phospholipase A2. Biochem Pharmacol 1989;38:3645-3651. 27. Radke S, Austermann J, Russo-Marie F, et al.: Specific association of annexin 1 with plasma membrane-resident and internalized EGF receptors mediated through the protein core domain. FEBS Lett 2004;578:95-98. 28. Kim YS, Ko J, Kim IS, et al.: PKCdelta-dependent cleavage and nuclear translocation of annexin A1 by phorbol 12-myristate 13-acetate. Eur J Biochem 2003;270:4089-4094. 29. Traverso V, Morris JF, Flower RJ, Buckingham J: Lipocortin 1 (annexin 1) in patches associated with the membrane of a lung adenocarcinoma cell line and in the cell cytoplasm. J Cell Sci 1998;111 ( Pt 10):1405-1418. 30. Errasfa M, Russo-Marie F: A purified lipocortin shares the anti-inflammatory effect of glucocorticosteroids in vivo in mice. Br J Pharmacol 1989;97:1051-1058. 31. Christmas P, Callaway J, Fallon J, et al.: Selective secretion of annexin 1, a protein without a signal sequence, by the human prostate gland. J Biol Chem 1991;266:2499-2507. 32. Huo XF, Zhang JW: Annexin1 regulates the erythroid differentiation through ERK signaling pathway. Biochem Biophys Res Commun 2005;331:1346-1352. 33. Garcia Pedrero JM, Fernandez MP, Morgan RO, et al.: Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004;164:73-79. 34. Skouteris GG, Schroder CH: The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor. J Biol Chem 1996;271:27266-27273. 35. Perretti M, Flower RJ: Measurement of lipocortin 1 levels in murine peripheral blood leukocytes by flow cytometry: modulation by glucocorticoids and inflammation. Br J Pharmacol 1996;118:605-610. 36. Walther A, Riehemann K, Gerke V: A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 2000;5:831-840. 37. Rescher U, Danielczyk A, Markoff A, Gerke V: Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J Immunol 2002;169:1500-1504. 38. Gavins FN, Kamal AM, D'Amico M, et al.: Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. FASEB J 2005;19:100-102. 39. Gavins FN, Yona S, Kamal AM, et al.: Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood 2003;101:4140-4147. 40. Bastian BC, Sellert C, Seekamp A, et al.: Inhibition of human skin phospholipase A2 by 'lipocortins' is an indirect effect of substrate/lipocortin interaction. J Invest Dermatol 1993;101:359-363. 41. Mukherjee AB, Miele L, Pattabiraman N: Phospholipase A2 enzymes: regulation and physiological role. Biochem Pharmacol 1994;48:1-10. 42. Chang J, Musser JH, McGregor H: Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol 1987;36:2429-2436. 43. Kim KM, Kim DK, Park YM, et al.: Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletion. FEBS Lett 1994;343:251-255. 44. Croxtall JD, Choudhury Q, Tokumoto H, Flower RJ: Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G protein-dependent activation of cPLA2 activity. Biochem Pharmacol 1995;50:465-474. 45. Constantinescu A, Pick U, Handelman GJ, et al.: Reduction and transport of lipoic acid by human erythrocytes. Biochem Pharmacol 1995;50:253-261. 46. Philip JG, Flower RJ, Buckingham JC: Glucocorticoids modulate the cellular disposition of lipocortin 1 in the rat brain in vivo and in vitro. Neuroreport 1997;8:1871-1876. 47. Solito E, Mulla A, Morris JF, et al.: Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 2003;144:1164-1174. 48. Strijbos PJ, Horan MA, Carey F, Rothwell NJ: Impaired febrile responses of aging mice are mediated by endogenous lipocortin-1 (annexin-1). Am J Physiol 1993;265:E289-297. 49. Yang YH, Hutchinson P, Leech M, Morand EF: Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. J Rheumatol 1997;24:1758-1764. 50. Taylor AD, Cowell AM, Flower J, Buckingham JC: Lipocortin 1 mediates an early inhibitory action of glucocorticoids on the secretion of ACTH by the rat anterior pituitary gland in vitro. Neuroendocrinology 1993;58:430-439. 51. Loxley HD, Cowell AM, Flower RJ, Buckingham JC: Effects of lipocortin 1 and dexamethasone on the secretion of corticotrophin-releasing factors in the rat: in vitro and in vivo studies. J Neuroendocrinol 1993;5:51-61. 52. Morand EF, Jefferiss CM, Dixey J, et al.: Impaired glucocorticoid induction of mononuclear leukocyte lipocortin-1 in rheumatoid arthritis. Arthritis Rheum 1994;37:207-211. 53. Goulding NJ, Jefferiss CM, Pan L, et al.: Specific binding of lipocortin-1 (annexin I) to monocytes and neutrophils is decreased in rheumatoid arthritis. Arthritis Rheum 1992;35:1395-1397. 54. Cuzzocrea S, Tailor A, Zingarelli B, et al.: Lipocortin 1 protects against splanchnic artery occlusion and reperfusion injury by affecting neutrophil migration. J Immunol 1997;159:5089-5097. 55. Davidson J, Flower RJ, Milton AS, et al.: Antipyretic actions of human recombinant lipocortin-1. Br J Pharmacol 1991;102:7-9. 56. Ferreira SH, Cunha FQ, Lorenzetti BB, et al.: Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol 1997;121:883-888. 57. Smith SF, Tetley TD, Guz A, Flower RJ: Detection of lipocortin 1 in human lung lavage fluid: lipocortin degradation as a possible proteolytic mechanism in the control of inflammatory mediators and inflammation. Environ Health Perspect 1990;85:135-144. 58. Smith SF, Tetley TD, Datta AK, et al.: Lipocortin-1 distribution in bronchoalveolar lavage from healthy human lung: effect of prednisolone. J Appl Physiol 1995;79:121-128. 59. Van Hal PT, Overbeek SE, Hoogsteden HC, et al.: Eicosanoids and lipocortin-1 in BAL fluid in asthma: effects of smoking and inhaled glucocorticoids. J Appl Physiol 1996;81:548-555. 60. Oliani SM, Paul-Clark MJ, Christian HC, et al.: Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression. Am J Pathol 2001;158:603-615. 61. Perretti M, Ahluwalia A, Harris JG, et al.: Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1. Br J Pharmacol 1996;117:1145-1154. 62. Rand JH: 'Annexinopathies'--a new class of diseases. N Engl J Med 1999;340:1035-1036. 63. Sullivan DM, Wehr NB, Fergusson MM, et al.: Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry 2000;39:11121-11128. 64. Kim J, Hajjar KA: Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 2002;7:d341-348. 65. Jans SW, de Jong YF, Reutelingsperger CP, et al.: Differential expression and localization of annexin V in cardiac myocytes during growth and hypertrophy. Mol Cell Biochem 1998;178:229-236. 66. Luckcuck T, Trotter PJ, Walker JH: Localization of annexin V in the adult and neonatal heart. Biochem Biophys Res Commun 1997;238:622-628. 67. Luckcuck T, Trotter PJ, Walker JH: Localization of annexin VI in the adult and neonatal heart. Cell Biol Int 1998;22:199-205. 68. Matteo RG, Moravec CS: Immunolocalization of annexins IV, V and VI in the failing and non-failing human heart. Cardiovasc Res 2000;45:961-970. 69. Kaneko N, Matsuda R, Toda M, Shimamoto K: Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative. Biochim Biophys Acta 1997;1330:1-7. 70. Hachida M, Lu H, Kaneko N, et al.: Protective effect of JTV519 (K201), a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation. Transplant Proc 1999;31:996-1000. 71. Gunteski-Hamblin AM, Song G, Walsh RA, et al.: Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. Am J Physiol 1996;270:H1091-1100. 72. Song G, Campos B, Wagoner LE, et al.: Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Mol Cell Cardiol 1998;30:443-451. 73. Benevolensky D, Belikova Y, Mohammadzadeh R, et al.: Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab Invest 2000;80:123-133. 74. Menell JS, Cesarman GM, Jacovina AT, et al.: Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004. 75. Rand JH: Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 2000;15:107-111. 76. Triplett DA, Asherson RA: Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 2000;65:154-159. 77. Wang X, Campos B, Kaetzel MA, Dedman JR: Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol 1999;180:1008-1016. 78. Bevers EM, Janssen MP, Willems GM, Zwaal RF: No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. Thromb Haemost 2000;83:792-794. 79. Kim GY, Lee HB, Lee SO, et al.: Chaperone-like function of lipocortin 1. Biochem Mol Biol Int 1997;43:521-528. 80. Rhee HJ, Kim GY, Huh JW, et al.: Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 2000;267:3220-3225. 81. Han EK, Tahir SK, Cherian SP, et al.: Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83:83-88. 82. Denko N, Schindler C, Koong A, et al.: Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000;6:480-487. 83. Tanaka T, Kondo S, Iwasa Y, et al.: Expression of stress-response and cell proliferation genes in renal cell carcinoma induced by oxidative stress. Am J Pathol 2000;156:2149-2157. 84. Gidrol X, Sabelli PA, Fern YS, Kush AK: Annexin-like protein from Arabidopsis thaliana rescues delta oxyR mutant of Escherichia coli from H2O2 stress. Proc Natl Acad Sci U S A 1996;93:11268-11273. 85. Kovacs I, Ayaydin F, Oberschall A, et al.: Immunolocalization of a novel annexin-like protein encoded by a stress and abscisic acid responsive gene in alfalfa. Plant J 1998;15:185-197. 86. Thonat C, Mathieu C, Crevecoeur M, et al.: Effects of a mechanical stimulation of localization of annexin-like proteins in Bryonia dioica internodes. Plant Physiol 1997;114:981-988. 87. Rand JH: ' Williams' Hematology.' New York: McGraw-Hill 2000. 88. Alldridge LC, Harris HJ, Plevin R, et al.: The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 1999;274:37620-37628. 89. Vishwanatha JK, Chiang Y, Kumble KD, et al.: Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 1993;14:2575-2579. 90. Chetcuti A, Margan SH, Russell P, et al.: Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001;61:6331-6334. 91. Roseman BJ, Bollen A, Hsu J, et al.: Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994;6:561-567. 92. Sato H, Ogata H, De Luca LM: Annexin V inhibits the 12-O-tetradecanoylphorbol-13-acetate-induced activation of Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of Shc in MCF-7 cells. Oncogene 2000;19:2904-2912. 93. Fleet A, Ashworth R, Kubista H, et al.: Inhibition of EGF-dependent calcium influx by annexin VI is splice form-specific. Biochem Biophys Res Commun 1999;260:540-546. 94. Theobald J, Hanby A, Patel K, Moss SE: Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells. Br J Cancer 1995;71:786-788. 95. Francia G, Mitchell SD, Moss SE, et al.: Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res 1996;56:3855-3858. 96. Srivastava M, Bubendorf L, Srikantan V, et al.: ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A 2001;98:4575-4580. 97. Kataoka TR, Ito A, Asada H, et al.: Annexin VII as a novel marker for invasive phenotype of malignant melanoma. Jpn J Cancer Res 2000;91:75-83. 98. Sarkar A, Yang P, Fan YH, et al.: Regulation of the expression of annexin VIII in acute promyelocytic leukemia. Blood 1994;84:279-286. 99. Chang KS, Wang G, Freireich EJ, et al.: Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 1992;79:1802-1810. 100. Frey BM, Reber BF, Vishwanath BS, et al.: Annexin I modulates cell functions by controlling intracellular calcium release. FASEB J 1999;13:2235-2245. 101. Oh J, Rhee HJ, Kim S, et al.: Annexin-I inhibits PMA-induced c-fos SRE activation by suppressing cytosolic phospholipase A2 signal. FEBS Lett 2000;477:244-248. 102. Vaarala MH, Porvari K, Kyllonen A, Vihko P: Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 2000;80:1259-1268. 103. Pencil SD, Toth M: Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 1998;16:113-121. 104. Masaki T, Tokuda M, Ohnishi M, et al.: Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996;24:72-81. 105. Bai XF, Ni XG, Zhao P, et al.: Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004;10:1466-1470. 106. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al.: An approach to proteomic analysis of human tumors. Mol Carcinog 2000;27:158-165. 107. Sinha P, Hutter G, Kottgen E, et al.: Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 1998;37:105-116. 108. de Bont JM, den Boer ML, Kros JM, et al.: Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol 2007;66:505-516. 109. Liu Y, Wang HX, Lu N, et al.: Translocation of annexin I from cellular membrane to the nuclear membrane in human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:645-649. 110. Paweletz CP, Ornstein DK, Roth MJ, et al.: Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-6297. 111. Hippo Y, Yashiro M, Ishii M, et al.: Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001;61:889-895. 112. Rodrigo JP, Garcia-Pedrero JM, Fernandez MP, et al.: Annexin A1 expression in nasopharyngeal carcinoma correlates with squamous differentiation. Am J Rhinol 2005;19:483-487. 113. Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, et al.: Annexin 1: differential expression in tumor and mast cells in human larynx cancer. Int J Cancer 2007;120:2582-2589. 114. Kang JS, Calvo BF, Maygarden SJ, et al.: Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 2002;8:117-123. 115. de Coupade C, Gillet R, Bennoun M, et al.: Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. Hepatology 2000;31:371-380. 116. Lin CY, Jeng YM, Chou HY, et al.: Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol 2008;97:544-550. 117. Oh P, Li Y, Yu J, et al.: Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629-635. 118. Hu N, Flaig MJ, Su H, et al.: Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:6013-6022. 119. Zhi H, Zhang J, Hu G, et al.: The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003;106:327-333. 120. Xia SH, Hu LP, Hu H, et al.: Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 2002;21:6641-6648. 121. Vishwanatha JK, Salazar E, Gopalakrishnan VK: Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. BMC Cancer 2004;4:8. 122. Falini B, Tiacci E, Liso A, et al.: Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869-1870. 123. Xin W, Rhodes DR, Ingold C, et al.: Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003;162:255-261. 124. Smitherman AB, Mohler JL, Maygarden SJ, Ornstein DK: Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J Urol 2004;171:916-920. 125. Patton KT, Chen HM, Joseph L, Yang XJ: Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. Histopathology 2005;47:597-601. 126. Mulla A, Christian HC, Solito E, et al.: Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. Clin Endocrinol (Oxf) 2004;60:107-119. 127. Ahn SH, Sawada H, Ro JY, Nicolson GL: Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 1997;15:151-156. 128. Shen D, Chang HR, Chen Z, et al.: Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun 2005;326:218-227. 129. Shen D, Nooraie F, Elshimali Y, et al.: Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 2006;37:1583-1591. 130. Sheng KH, Yao YC, Chuang SS, et al.: Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 2006;6:1058-1065. 131. Xiao GS, Jin YS, Lu QY, et al.: Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer 2007;120:111-120. 132. Chen YS, Wang JT, Chang YF, et al.: Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004;33:209-217. 133. 'Pathology and Genetics of Head and Neck Tumors.' Lyon, France: IARCPress, 2005. 134. Ulaner GA, Hu JF, Vu TH, et al.: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998;58:4168-4172. 135. Kamata N, Yokoyama K, Fujimoto R, et al.: Growth of normal oral keratinocytes and squamous cell carcinoma cells in a novel protein-free defined medium. In Vitro Cell Dev Biol Anim 1999;35:635-641. 136. Fassetta M, D'Alessandro L, Coltella N, et al.: Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal 2006;18:1967-1976. 137. Wang KL, Wu TT, Resetkova E, et al.: Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 2006;12:4598-4604. 138. Kang SA, Cho YJ, Moon HB, Na DS: Translocation of lipocortin (annexin) 1 to the membrane of U937 cells induced by phorbol ester, but not by dexamethasone. Br J Pharmacol 1996;117:1780-1784. 139. Serres M, Comera C, Schmitt D: Annexin 1 regulation in human epidermal cells. Cell Mol Biol (Noisy-le-grand) 1994;40:701-706. 140. Sato-Matsumura KC, Matsumura T, Nakamura H, et al.: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res 2000;292:496-499. 141. White IJ, Bailey LM, Aghakhani MR, et al.: EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation. Embo J 2006;25:1-12. 142. Solito E, de Coupade C, Parente L, et al.: IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein. Cytokine 1998;10:514-521. 143. Solito E, Christian HC, Festa M, et al.: Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface. Faseb J 2006. 144. Novak A, Dedhar S: Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 1999;56:523-537. 145. Ma AS, Ozers LJ: Annexins I and II show differences in subcellular localization and differentiation-related changes in human epidermal keratinocytes. Arch Dermatol Res 1996;288:596-603. 146. Xia W, Lau YK, Zhang HZ, et al.: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-4174. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40503 | - |
dc.description.abstract | 在正常口腔黏膜,ANX A1主要表現在細胞膜,但在分化良好的細胞核亦見其表現;在上皮變異(OED)的病例,則有位置移轉的現象:自細胞膜移向細胞質,或細胞核;而口腔鱗狀上皮細胞癌(OSCC)的病例則,可見ANX A1在細胞核的表現,有增加的現象,其中在OED核的正表現比率為13.64%,即66個病例有9個有正表現;而OSCC則在115個病例中有63個細胞核正表現的現象(54.8%)。其中以Kaplan-Meier曲線分析,顯示OSCC的細胞核陽性表現與較短的存活率,在統計上有意義的相關(P:0.00036)。多變數分析(stepwise multivariate logistic-regression model),則顯示出ANX A1核染色可用來做一為較差存活的指標。另外,在口腔鱗狀上皮細胞癌細胞株SAS,投予肝生長因子(HGF)可誘發ANX A1蛋白質自細胞膜質移向細胞核。而以PI3K的抑制劑LY294002幾乎可以完全抑制(88.3%)由HGF所引起的ANX A1之細胞核移轉。 | zh_TW |
dc.description.abstract | To investigate whether annexin A1 (ANXA1) expression is a marker in predicting the prognosis of oral cancer patients. We immunohistochemically examined the expression of ANXA1 in 66 cases of oral epithelial dysplasia (OED) and 115 cases of oral squamous cell carcinoma (OSCC). The results were correlated with the clinicopathological parameters of tumors and overall patient survival. In normal oral mucosa, ANXA1 staining was predominantly located on the cell membrane. In OED and OSCC specimens, membranous staining decreased, whereas nuclear staining increased. Positive nuclear staining was observed in 9 of 66 (13.64%) OED cases and 63 of 115 (54.8%) OSCCs. Kaplan–Meier curves showed that OSCC patients with ANXA1 nuclear staining had significantly shorter overall lengths of survival (P¼0.00036 by the log-rank test). Multivariate analysis showed that ANXA1 nuclear staining is a significant predictor of poor overall survival. And oral cancer SAS cells treated with hepatocyte growth factor (HGF) can induce ANXA1 protein translocation from cytoplasm to nucleus. Cells pretreated with LY294002 (PI3K inhibitor) almost completely inhibited (88.3% inhibition) HGF-mediated ANXA1 nuclear translocation. The nuclear localization of ANXA1 protein is a frequent event and could be used as a prognostic factor in OSCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T16:49:32Z (GMT). No. of bitstreams: 1 ntu-97-D88422001-1.pdf: 2993269 bytes, checksum: f83d595e645097f03e111f02960d0fa5 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………………………………………………I
誌謝…………………………………………………………………………………II 中文摘要……………………………………………………………………………III 英文摘要……………………………………………………………………………IV 第一章 序論 1.1 第一節 口腔鱗狀細胞癌(OSCC) ……………………………………… 1 1.2 第二節 Annexin 家族導論 (Introduction: Overview of the Annexin Family)………… 2 1.2.1 基因組成與演化歷史 (Gene organization & revolutionary history) …………… 2 1.2.2 結構特色(Characteristic structural features) …………… 3 1.2.3 位置與多元化功能(Localization & Functional Diversity)… 5 1.2.3.1 Annexin 通論………………………………………………… 5 1.2.3.2 ANX A1 個論…………………………………………………… 7 1.3 第三節 Annexin 與疾病的關係 (Annexin and Diseases) ……… 11 1.3.1 心臟與循環的疾病 (Disorders of the Heart and Circulation) …… 11 1.3.1.1 Annexin及心血管切片(Annexins and cardiova scular biology)11 1.3.1.2 心臟疾病 (Heart diseases) ……………………………… 12 1.3.1.3 Annexin 與抗凝血 (Annexins as anticoagulants) …………… 13 1.3.2 ANX與生理學壓力(Annexins and Physiological Stress) ……………14 1.3.3 ANX 與其他疾病…………………………………………………… 15 1.3.4. ANX 與癌症(Annexins and Cancer) …………………………………15 1.3.4.1 ANX 與癌症………………………………………………………16 1.3.4.2 ANX A1 與癌症(見表1) ………………………………………17 第二章 材料與方法……………………………………………………………… 23 2.1 第一節 檢體之取樣與收集…………………………………………… 23 2.1.1 臨床資料…………………………………………………………… 23 2.1.2 標本之採集………………………………………………………… 23 2.1.3 標本之處理………………………………………………………… 24 2.2 第二節 實驗方法……………………………………………………… 24 2.2.1 蘇木紫與伊紅染色………………………………………………… 24 2.2.2 免疫組織化學染色………………………………………………… 24 2.2.2.1 原理免疫組織化學染色……………………………………… 24 2.2.2.2 實驗步驟……………………………………………………… 26 2.2.3 組織病理檢查及組織學分類……………………………………… 28 2.2.4 組織之核糖核酸萃取 (Total RNA extraction from tissues) 28 2.2.5 反轉錄-聚合酶鏈鎖反應(RT-PCR)……………………………… 29 2.2.6 細胞培養(Cell culture) ………………………………………… 31 2.2.7 抑制劑的處理 (inhibitor treatment) ………………………… 32 2.2.8 免疫螢光染色 (Immunofluorescence Stains) ………………… 33 2.2.9 西方墨點法 (Western blot) …………………………………… 33 2.3 第三節 試劑 (Reagent) …………………………………………… 35 2.4 第四節 溶液備製……………………………………………………… 35 2.5 第五節 統計方法……………………………………………………… 36 第三章 結果……………………………………………………………………… 37 3.1 第一節 ANX A1 在口腔正常上皮(normal oral epithelial, NOE)口腔 上皮變異(oral epithelial dysplasia ,OED)及口腔鱗狀上皮癌(OSCC)的表 現…………………………………………………………………………………… 37 3.2 第二節 免疫化學組織染色結果與臨床病理因子的關係…………… 37 3.3 第三節 以反轉錄-聚合酶鏈鎖反應(RT-PCR)的方式,探討ANX A1 在 口腔鱗狀上皮細胞癌組織的表現 ………………………………………38 3.4 第四節 肝生長激素刺激ANX A1 且細胞質移位至細胞核於口腔鱗狀上 皮癌細胞株SAS (Stimulation of ANXA1 Nuclear Translocation in Human Oral Cancer SAS Cells by HGF) ………………………………………………………………………38 3.5 第五節 由HGF 引起的ANX A1 核移位經由PI3K 訊息傳導路徑 …… 39 3.6 第六節 ANX A1 在口腔鱗狀上皮細胞癌細胞株的表現(Annexin AI mRNA expression in the oral SCC cell lines) ………………………… 40 3.6.1 mRNA 的表現………………………………………………………… 40 3.6.2 蛋白質的表現……………………………………………………… 40 3.6.3 ANX A1 在台灣口腔鱗狀上皮細胞癌細胞株TW2.6 的表現……… 41 3.7 第七節 補遺資料(Supplement Data) ……………………………… 41 3.7.1 c-met 免疫組織化學染色………………………………………… 41 第四章 討論……………………………………………………………………… 42 參考文獻…………………………………………………………………………… 47 附錄-圖………………………………………………………………………………58 表………………………………………………………………………………64 發表文章(Publications) …………………………………………………………69 | |
dc.language.iso | zh-TW | |
dc.title | Annexin A1基因表現在口腔鱗狀細胞癌之研究 | zh_TW |
dc.title | Annexin A1 expression in oral squamous cell carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 許輝吉 | |
dc.contributor.oralexamcommittee | 江俊彬,張國威,張龍昌 | |
dc.subject.keyword | ANX A1,口腔鱗狀上皮細胞癌,細胞核移轉, | zh_TW |
dc.subject.keyword | annexin A1,oral squamous cell carcinoma,nuclear translocation, | en |
dc.relation.page | 69 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 2.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。